

Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. and its subsidiary Avrio Health L.P.

Purdue Pharma L.P. and its subsidiary Avrio Health L.P. has recalculated its 340B ceiling prices for 2019, time periods Q1, Q2, Q3, and Q4, for various products. Products whose ceiling price were impacted by revisions to their Medicaid pricing data and where purchases existed are listed below. Also listed are the relevant 340B ceiling price quarters for which the ceiling price of that product was impacted. Purdue has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the HRSA public website to ensure transparency by providing access to information about Purdue’s recalculation affecting certain 340B Covered Entities for the impacted Purdue product.

Purdue has determined the credit amount owed to each affected covered entity. Purdue will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each affected Covered Entity. If a wholesaler account is identified, Purdue will issue a credit to the Covered Entity through the wholesaler, and a check will be issued to Covered Entities whose wholesaler account cannot be identified. If a Covered Entity believes they are due a refund and are not contacted by Apexus within a month after the posting of this notice, you may contact Alicia Graziano, Purdue Pharma L.P. Director of Government and Institutional Contract Ops, at Alicia.Graziano@pharma.com.

<u>NDC</u>	<u>Product Description</u>	<u>Period</u>
59011025530	Intermezzo 3.5 mg sublingual tablets (30 unit-dose pouches/carton)	Q1 2019
59011025630	Intermezzo 1.75 mg sublingual tablets (30 unit-dose pouches/carton)	Q1 2019
59011027260	Hysingla ER 30mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011027360	Hysingla ER 40mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011027460	Hysingla ER 60mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011027560	Hysingla ER 80mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011027660	Hysingla ER 100mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011027760	Hysingla ER 120mg Extended Release tablets CII	Q1 Q2 Q3 Q4 2019
59011046010	OxyContin 60 mg. Extended Release tablets CII 100's	Q1, Q2 2019
59011048010	OxyContin 80 mg. Extended Release tablets CII 100's	Q1, Q2, Q4 2019
59011075004	Butrans 5 mcg/hour Transdermal System CIII (4 systems/carton)	Q1 2019
59011075104	Butrans 10 mcg/hour Transdermal System CIII (4 systems/carton)	Q1 2019

59011075804	Butrans 15 mcg/hour Transdermal System CIII (4 systems/carton)	Q1 2019
	Butrans 20 mcg/hour Transdermal System CIII (4 systems/carton)	Q1 Q2 2019
59011075204		
67618010160	Colace Capsules 100mg (60 count bottle)	Q4 2019
67618015008	Betadine Solution 80z. Retail	Q4 2019
67618015301	Betadine Solution Swab stick 1s	Q4 2019
67618015303	Betadine Solution Swab stick 3s	Q4 2019